GABAPENTIN | A075350 | ACTAVIS ELIZABETH LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition Amendment from Rising Pharma Holdings, Inc. FDA-2026-P-5123 · 6 docket documents Rising Pharma Holdings, Inc. filed an amendment to its suitability petition regarding the regulatory pathway and approval process for an unnamed drug product. The specific requested action, drug name, and regulatory mechanism such as NDA or ANDA approval are not detailed in the provided title and co | Suitability | 2026-06-05 | Open | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0428
per ea
Lowest NADAC/Unit
$0.0219
per ea
Brand NDCs
0
Generic NDCs
8
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 45963055750GABAPENTIN 400 MG CAPSULE | $0.0428 | EA | Generic | — | 2026-10-21 |
| 45963055711GABAPENTIN 400 MG CAPSULE | $0.0428 | EA | Generic | — | 2026-10-21 |
| 45963055611GABAPENTIN 300 MG CAPSULE | $0.0328 | EA | Generic | — | 2026-10-21 |
| 00480349505GABAPENTIN 300 MG CAPSULE | $0.0328 | EA | Generic | — | 2026-10-21 |
| 45963055650GABAPENTIN 300 MG CAPSULE | $0.0328 | EA | Generic | — | 2026-10-21 |
| 45963055511GABAPENTIN 100 MG CAPSULE | $0.0219 | EA | Generic | — | 2026-10-21 |
| 45963055550GABAPENTIN 100 MG CAPSULE | $0.0219 | EA | Generic | — | 2026-10-21 |
| 00480349405GABAPENTIN 100 MG CAPSULE | $0.0219 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.